Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mixed sentiment. Strong product development updates and international expansion are positive, but lack of specific guidance and unclear management responses in the Q&A create uncertainty. No major catalysts like partnerships or guidance changes were noted, leading to a neutral prediction for stock movement.
Key Financial Performance
Cash, cash equivalents and restricted cash $213.4 million on March 31, 2026, compared to $232.8 million on December 31, 2025. This represents a decrease, attributed to operational expenses and strategic refocusing.
Year-over-year quarterly revenue Decreased by $27.3 million. The decline was driven by reductions in revenue from the CSL collaboration as Arcturus refocuses on rare disease clinical programs.
Quarterly research and development expenses Decreased year-over-year by $13.4 million. This was primarily due to lower manufacturing costs related to LUNAR-COVID and BARDA, reduced clinical trial costs for the LUNAR-COVID program, and lower payroll and benefit costs due to reduced stock-based compensation and headcount. However, there were partially offsetting increases in manufacturing costs related to LUNAR-OTC.
General and administrative expenses Decreased year-over-year by $1.8 million. This was due to reduced share-based compensation expense and payroll and benefits associated with reductions in headcount.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ARCT-032 (Inhaled mRNA CF Therapeutic): Enrollment for a 12-week Phase II study began in Q1 2026. This study is designed to monitor safety, tolerability, and lung function measures for Class I CF patients. The technology uses unique LUNAR particle technology and proprietary mRNA manufacturing processes to ensure tolerability and safety.
ARCT-810 (mRNA Therapeutic for OTC Deficiency): The FDA provided clear regulatory direction for a pivotal pediatric study. Additional exploratory data is being collected, with an end of Phase II meeting planned for the second half of 2026.
KOSTAIVE (Self-amplifying mRNA COVID Vaccine): Manufactured by partner Meiji in Japan for the 2026-2027 season. Commercial guidance will be provided by Meiji.
Financial Performance: Cash, cash equivalents, and restricted cash totaled $213.4 million as of March 31, 2026. Quarterly revenue decreased by $27.3 million year-over-year due to reduced CSL collaboration revenue. R&D expenses decreased by $13.4 million, driven by lower manufacturing and clinical trial costs for LUNAR-COVID.
Leadership Expansion: Dennis Mulroy was appointed as CFO and Dr. Alan Cohen as CMO, both bringing extensive experience to support clinical, regulatory, and corporate priorities.
Strategic Refocusing: The company is refocusing on rare disease clinical programs, reducing costs associated with LUNAR-COVID and reallocating resources to ARCT-032 and ARCT-810 programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Year-over-year quarterly revenue decreased by $27.3 million, driven by reductions in revenue from the CSL collaboration as the company refocuses on rare disease clinical programs.
R&D Expense Reduction: Quarterly research and development expenses decreased by $13.4 million year-over-year, primarily due to lower manufacturing costs related to LUNAR-COVID and BARDA, as well as reduced clinical trial costs associated with the LUNAR-COVID program. This could impact the pace of innovation and development.
Headcount Reduction: Reductions in headcount contributed to lower payroll and benefit costs, which may affect operational capacity and efficiency.
Regulatory and Clinical Risks: The company is dependent on successful regulatory alignment and clinical trial outcomes for its ARCT-032 and ARCT-810 programs. Any delays or failures in these areas could significantly impact strategic objectives.
Market Dependency: The success of the ARCT-032 and ARCT-810 programs is heavily reliant on addressing unmet medical needs in niche markets, which could limit scalability and revenue potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ARCT-032 (Cystic Fibrosis): Enrollment is underway for a 12-week open-label Phase II study targeting Class I CF mutations. The study aims to monitor safety, tolerability, and early clinical benefits, including lung function measures such as percent predicted FEV1 and lung clearance index. The study also evaluates quality of life outcomes and high-resolution CT imaging to assess clinical effects. The goal is to establish the feasibility of repeated dosing for durable benefits.
ARCT-810 (OTC Deficiency): The FDA has provided clear regulatory direction for a pivotal pediatric study. Additional exploratory data is being collected to establish optimal dosing and therapeutic effects. An end-of-Phase II meeting with the FDA is planned for the second half of 2026 to align on the development path.
KOSTAIVE (COVID Vaccine): The self-amplifying mRNA COVID vaccine is being manufactured by Meiji in Japan for the 2026-2027 season. Commercial guidance for this product in Japan will be provided by Meiji.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you share specific FDA feedback on the glutamine and ureagenesis assay for OTC deficiency, and discuss the path forward for infants and adults?
A:The FDA provided clarity on the biomarkers to use, particularly ammonia and glutamine. Ureagenesis is still in development, and its dependence will rely on additional data being generated. The path forward for infants and adults is clearer now.
Q:What updates can you share on patient enrollment and progress for the cystic fibrosis (CF) study?
A:The cadence of enrollment is being determined in the upcoming weeks. The study started in Q1, and more accurate enrollment completion timing will be available later this year. Enrollment is expanding beyond the U.S. to international sites.
Q:What exploratory data is the FDA looking for in the OTC program, and will it require studies in the pediatric population?
A:The FDA is looking for additional enrollment data for the 0.3 and 0.5 dosing groups. The goal is to show safety, tolerability, and clinical efficacy to justify moving into the pediatric population. Sufficient data is expected later this year to proceed with pediatric studies.
Q:How should we interpret the CF study data without a placebo control, particularly regarding FEV1 and LCI variability?
A:The study collects two lung function parameters, FEV1 and LCI, with measures taken at consistent intervals. LCI is a sensitive tool for measuring changes in small airways. The FDA has not defined a threshold of success for FEV1 or LCI for this program, and any positive results will be taken seriously.
Q:Have you observed any issues similar to those that led a competitor to discontinue its inhaled CFTR mRNA trial?
A:No, there are significant differences in technology, chemistry, and manufacturing processes. The company does not use steroids as a co-treatment and has been approved for unsupervised dosing at home, differentiating it from competitors.
Q:Are there go/no-go decisions built into the CF study protocol based on tolerability or efficacy?
A:Yes, the open-label design allows for active monitoring of safety signals and early signs of efficacy. By the end of the year, sufficient data should be available to assess the program's future direction.
Q:What are your plans for combining your CF therapy with a modulator or targeting non-responder populations?
A:The therapy could potentially benefit a broader population, including those on modulators, but sufficient data needs to be generated first. The focus remains on the highest unmet need population, such as those with null mutations.
Q:When can we expect the outcome of the adult Type C meeting for OTC?
A:The second Type C meeting is expected to be completed this quarter, as planned for the first half of the year.
Q:How is the team segmenting pediatric, adolescent, and adult populations for OTC, and what is the realistic enrolled patient number for the pediatric pivotal study?
A:The focus is on children under age 6, as they have the highest unmet need. The pediatric pivotal study will target this population, which often faces severe outcomes like liver transplants or death if untreated.
Q:Will there be interim disclosures for the CF study given its open-label design?
A:The company expects to have sufficient enrollment and data later this year to inform next steps, but specific interim disclosures have not been detailed.
Q:What preclinical data supports LUNAR-CF's ability to penetrate mucus and produce functional protein?
A:Preclinical studies in mouse, ferret, and nonhuman primate models show broad distribution to bronchial epithelial cells. The nebulizer has been optimized for particle size to ensure distribution throughout the lung.
Q:Are you addressing drug distribution to the lower lobes of the lung in the CF study?
A:The nebulizer has been optimized for particle size to ensure even distribution. The 12-week dosing strategy is expected to improve drug application throughout the lung.
Q:Do you need to enroll more patients at specific doses for the OTC exploratory data?
A:No, the current study needs to be completed as scheduled, with data analyzed and presented as requested by the FDA.
Q:How frequently are HRCT scans, LCI, and FEV1 measurements conducted in the CF study?
A:HRCT scans are conducted before and after the study. LCI and FEV1 measurements are taken at regular intervals when patients return to the clinic.
Q:Are you enrolling a specific number of CF patients outside the U.S.?
A:The protocol allows for up to 20 subjects, with an anticipated equal mix of U.S. and international patients.
Q:How are you allocating resources between adult and pediatric OTC programs?
A:The adult program is nearly complete, and the focus will shift to the pediatric program once sufficient data is generated and the FDA provides approval to proceed.
Q:Is the OTC therapy intended as a stopgap before liver transplantation or as a long-term treatment?
A:The therapy aims to prevent the need for liver transplantation and provide a long-term treatment option for children with OTC deficiency.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of interim disclosures for the CF study, stating only that sufficient data would be available later this year. Additionally, they did not provide granular details on resource allocation between adult and pediatric OTC programs, focusing instead on general priorities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARCT
CF Class
CF disease
Chief Medical
Class CF
Class mutation
II meeting
II study
LUNAR COVID
Medical Officer
Mulroy Chief
Officer Dr
Phase II
approach
benefit
cash
clearance index
development
direction
disease program
dosing month
feasibility
function measure
label Phase
lung clearance
measure change
need
percent
reduction
safety tolerability
ARCT Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary indicates a mixed sentiment. Strong product development updates and international expansion are positive, but lack of specific guidance and unclear management responses in the Q&A create uncertainty. No major catalysts like partnerships or guidance changes were noted, leading to a neutral prediction for stock movement.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call revealed strong financial performance with a significant increase in revenue and net income, driven by the mRNA platform and cost management. The increase in R&D expenses indicates ongoing investment in clinical trials, suggesting future growth potential. The operational cash flow also improved, supporting financial health. Despite some risks associated with forward-looking statements, the overall financial metrics and strategic investment in R&D provide a positive outlook for the stock price movement over the next two weeks.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Unknown8-11
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
ARCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
